Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Evotec AG has announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 4.0 million to Evotec.
The milestone was for the transition of a respiratory programme into pre-clinical development.
Dr Mario Polywka, Chief Operating Officer of Evotec commented: “This is the sixteenth milestone achieved as part of our alliance with Boehringer Ingelheim and represents an important transition of this programme into pre-clinical development. The alliance continues to achieve significant scientific and commercial success, reflecting the truly collaborative efforts of teams from Evotec and Boehringer Ingelheim.”
